The Recall Desk
SevereFDA (Drugs)·D-068-2013·Announced 2012-12-05

GlaxoSmithKline Recalls Arranon Injection Due to Potential Impurities

GlaxoSmithKline is recalling specific lots of Arranon (nelarabine) Injection because drug-related impurities may exceed specification limits.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), as the agency's own classification mandates a score of at least 4.

Plain-English summary

GlaxoSmithKline, LLC. is recalling 1,319 vials of Arranon (nelarabine) Injection 5mg/mL, 50mL Vials. The affected product is prescription-only and intended for intravenous infusion. The recall covers lots C536707, C538830, and C533169, all with an expiration date of 02/14. The product was distributed nationwide.

The recall was initiated because there is a potential for drug-related impurities to exceed specification limits. The agency has classified this recall as Class II.

Healthcare providers and patients should stop using the affected lots of Arranon and contact their healthcare provider or GlaxoSmithKline for further instructions.

The recalled product

Product
Arranon (nelarabine) Injection 5mg/mL, 50mL Vials, Rx only, For I.V. Infusion only, GlaxoSmith Kline, Research Triangle Park, NC 27709. Made in England, NDC 0007-4401-06
Manufacturer
GlaxoSmithKline, LLC.
Category
Drug — Injection
Hazard
Affected units
1,319

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lot # C536707 Exp 02/14
  • C538830 Exp.02/14
  • C533169 Exp. 02/14

Distribution

Distributed nationwide across the United States.

Related recalls

Same manufacturer · GlaxoSmithKline, LLC.

See all →

Same hazard · impurities

See all →